Ipsen races towards US profitability a year early
This article was originally published in Scrip
Executive Summary
A turnaround in Ipsen's US business is underpinning a transformation at the mid-sized French pharmaceutical company, which is planning to narrow its focus to niche therapeutic areas including gastrointestinal endocrine tumors and antispasticity neurotoxins. The company's CEO says it is now on track to reach US profitability one year earlier than forecast.